Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

PMA reports allowed on bienniel basis under Reinventing Government initiative.

This article was originally published in The Gray Sheet

Executive Summary

PMA REPORT SUBMISSIONS ON BIENNIAL RATHER THAN ANNUAL BASIS is among FDA device reporting deadline modifications proposed by the agency in response to President Clinton's April request to reduce the frequency of reports under federal regulations. In a summary of a report of HHS reform initiatives released the week of Sept. 4, the department said that FDA "can extend to biennial" the current annual time frame for submission of postmarket reports for devices with cleared premarket approval applications.

Latest Headlines
See All
UsernamePublicRestriction

Register

MT004687

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel